INSMED INC Deferred Foreign Income Tax Expense (Benefit)
INSMED INC (INSM) reported Deferred Foreign Income Tax Expense (Benefit) of $0 for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-19.
Financial Statements › Expense Statement › Income Tax
us-gaap:DeferredForeignIncomeTaxExpenseBenefit · last filed 2026-02-19
- INSMED INC deferred foreign income tax expense (benefit) for fiscal 2025 was $0.00.
- INSMED INC deferred foreign income tax expense (benefit) for fiscal 2024 was $0.00.
- INSMED INC deferred foreign income tax expense (benefit) for fiscal 2023 was $0.00.
- INSMED INC deferred foreign income tax expense (benefit) for fiscal 2022 was $0.00.
| Period end | Deferred Foreign Income Tax Expense (Benefit) 12 month |
|---|---|
| 2025-12-31 | $0.00 10-K · filed 2026-02-19 |
| 2024-12-31 | $0.00 10-K · filed 2026-02-19 |
| 2023-12-31 | $0.00 10-K · filed 2026-02-19 |
| 2022-12-31 | $0.00 10-K · filed 2025-02-20 |
| 2021-12-31 | $0.00 10-K · filed 2024-02-22 |
| 2020-12-31 | $0.00 10-K · filed 2023-02-23 |
| 2019-12-31 | $0.00 10-K · filed 2022-02-17 |
| 2018-12-31 | $0.00 10-K · filed 2021-02-25 |
| 2017-12-31 | $0.00 10-K · filed 2020-02-25 |
| 2016-12-31 | $0.00 10-K · filed 2019-02-22 |
| 2015-12-31 | $0.00 10-K · filed 2018-02-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |